On October 15, Pfizer Pharmaceuticals announced that HYMPAVZI (marstacimab-hncq) has recently been approved by the Food and Drug Administration (FDA) in the USA for the routine treatment of hemophilia A (congenital clotting factor VIII deficiency) or hemophilia B (congenital clotting factor IX deficiency) patients aged 12 and older without clotting factor inhibitors, to reduce the incidence of bleeding. HYMPAVZI is the second hemophilia treatment drug approved by Pfizer this year.